Importantly, the combined cumulative endpoint (i.e., defined as recurrent stroke, mortality and severe disability) of this study during long-term follow-up was markedly greater in the control group than in the cell-treated group, suggesting that the favorable outcomes in cell-treated group are potentially due to CD34 + treatment. Here, CD34 is linked to stroke disorder.